Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine Antimoniate Dosage in American Cutaneous Leishmaniasis
NCT01301924Phase 3Completed
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Oct 2008
- Primary completion
- Apr 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Fundação Oswaldo Cruz. Primary endpoint: Effectiveness of meglumine antimoniate treatment at 6 years. Started Oct 2008; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01301924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301924.